The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

US FDA approves Bio-Thera Solutions & Hikma Pharma’s Starjemza injection, a biosimilar referencing Stelara injection: Guangzhou Wednesday, May 28, 2025, 17:00 Hrs [IST] Bio-Ther ...

Studies show that people with psoriasis, especially those with severe cases, have a much higher risk of heart disease than ...

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.